Nutritional Supplement of Phytochemical in Prevention of AMD
Principal Investigator
Nawajes Mandal, PhD
University of Oklahoma Health Sciences Center
Oklahoma City, OK, USA
About the Research Project
Program
Award Type
Standard
Award Amount
$100,000
Active Dates
April 01, 2009 - March 31, 2012
Grant ID
M2009083
Goals
The efficacy of known potent anti-inflammatory and anti-oxidative botanical compounds such as curcumin, sulforaphane, and caffeic acid phenethyl ester (CAPE) will be tested in animal models of retinal degeneration. The protective effect of these compounds on cell death will also be tested in cultured retina-derived cells. The mechanism of action of these compounds in retinal protection will be determined. As age-related macular degeneration (AMD) develops from oxidative stress and chronic inflammation, we hope to find a promising compound that can be tested further in pre-clinical and clinical trials.
Summary
Age-related macular degeneration (AMD) is a multifactorial disease associated with age. It is, therefore, extremely challenging to develop effective therapies against AMD. Research has identified that oxidative stress and inflammation are integral to the cause, development, and effects of AMD. Nutritional supplementation of anti-inflammatory and anti-oxidative compounds holds promises for the least costly and most practical way to delay the onset of AMD and thus protect vision. We have, therefore, selected three botanical compounds that have been in human consumption for hundreds of years as traditional medicines and have been shown to possess potent anti-inflammatory and anti-oxidative properties. As the compounds are plant-derived and non-toxic at fairly high doses, discovering their role in retinal protection will pave the way for a clinical trial of a promising compound for augmentative therapy of AMD.
In this project, we will:
- Determine the protective role of curcumin (from Turmeric), sulforaphane (from Broccoli), and caffeic acid phenethyl ester (from Honeybee propolis) in acute and chronic models of light-induced retinal degeneration in rats; and
- Determine the mechanism(s) of curcumin-, sulforaphane-, and caffeic acid phenethyl ester-mediated protection of the retina from light-induced damage and retinal cell lines (661W, ARPE-19) from oxidant-induced damage.
This project will open up new directions for testing the efficacy of other derivatives of these compounds or other promising compounds that may provide better protection from AMD when supplied through diet.
Project Updates
Dr. Mandal’s team has determined that dietary supplements made of plant-derived natural compounds—such as curcumin (from turmeric), sulforaphane (SF, from cruciferous vegetables such as broccoli), and caffeic acid phenethyl ester (CAPE, from honeybee propolis)—have protective effects on the retina of rats that have been stressed with intense light exposure (a model of AMD). Curcumin and sulforaphane showed better protection than CAPE. However, CAPE preserved retinal function in rats.
In order to understand how these compounds exert their protective function, the team applied the above-mentioned compounds to mouse retina cells cultured in plates. Following this pre-treatment, the cells were exposed to oxidant stress. Then the team studied their mechanism of action using several biochemical and molecular methods. Pretreatment with curcumin as well as CAPE significantly induced an enzyme (protein) called “Heme Oxygenase 1,” even without applying oxidant stress. Heme Oxygenase 1 is a potent defense molecule against oxidant and inflammatory stress. When Dr. Mandal’s team fed curcumin to rats, this supplement inhibited activation of a protein called NF-kB, activation of which is responsible for inducing inflammation and cell death in the retina. A compound that has potential to induce cellular defense mechanism against oxidative stress and inflammation may have tremendous therapeutic possibilities as a supplement for nutritional and augmentative therapy of AMD.
Grants
Related Grants
Macular Degeneration Research
Investigating AMD-Like Disease in Animal Models
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Brittany Carr, PhD
Investigating AMD-Like Disease in Animal Models
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Brittany Carr, PhD
Macular Degeneration Research
The Generation of Cone Photoreceptor Outer Segments
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Heike Kroeger, PhD
The Generation of Cone Photoreceptor Outer Segments
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Heike Kroeger, PhD
Macular Degeneration Research
Innovative Night Vision Tests for Age-Related Macular Degeneration
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Maximilian Pfau, MD
Innovative Night Vision Tests for Age-Related Macular Degeneration
Active Dates
July 01, 2024 - June 30, 2027
Principal Investigator
Maximilian Pfau, MD